CAJ | 학술논문

目的:观察国产吉西他滨(GEM,泽菲)联合顺铂(PDD)组成的GP方案治疗中晚期非小细胞肺癌(NSCLC)的疗效及毒副作用.方法:42例经病理或细胞学证实的中晚期非小细胞肺癌患者,采用GP方案化疗,GEM 1 000 mg/m2第1天、第8天静滴,PDD 80 mg/m2第1天静滴,21 d为1个周期,使用2～4个周期.结果:42例中,完全缓解(CR)2例(4.76%),部分缓解(PR)17例(40.48%),稳定(SD)14例(33.33%),进展(PD)9例(21.42%),客观有效率(RR=CR+PR)为45.24%(19/42).毒副作用主要表现为血白细胞、血小板下降,恶心呕吐等,但均可耐受.结论:吉西他滨联合顺铂治疗中晚期非小细胞肺癌有较好的疗效,毒副作用可耐受,值得临床推广应用.
목적:관찰국산길서타빈(GEM,택비)연합순박(PDD)조성적GP방안치료중만기비소세포폐암(NSCLC)적료효급독부작용.방법:42례경병리혹세포학증실적중만기비소세포폐암환자,채용GP방안화료,GEM 1 000 mg/m2제1천、제8천정적,PDD 80 mg/m2제1천정적,21 d위1개주기,사용2～4개주기.결과:42례중,완전완해(CR)2례(4.76%),부분완해(PR)17례(40.48%),은정(SD)14례(33.33%),진전(PD)9례(21.42%),객관유효솔(RR=CR+PR)위45.24%(19/42).독부작용주요표현위혈백세포、혈소판하강,악심구토등,단균가내수.결론:길서타빈연합순박치료중만기비소세포폐암유교호적료효,독부작용가내수,치득림상추엄응용.
Objective: To observe the therapeutic effect and side effect of Gemcitabine combined and Cisplatin in the intermediate-advanced stage of non-smaU cell lung cancer (NSCLC). Methods: 42 patients with advanced NSCLC enrolled in allotted to the study. The patients were treated with GP regiment, GEM 1 000 mg/m2, dl and d8 intravenous infusion. PDD 80 mg/m2 dl intravenous infusion. 21 days for one cycle,all patients received 2--4 cycles therapies. Results: In 42 cases, CR 2 eases (4.76%),PR 17 cases (40.48%),SD 14 cases (33.33%),PD 9 cases (21.42%),RR(CR+PR) was 45.24% (19/42). The main side effects were leucopeenia,thrombocytopenia,gastro-intestinal reaction. Conclusion: Gemcitabine andcisplatin in the treatment of advanced non-small cell lung cancer have better efficacy, side effects can be tolerated, it is worth clinical application.